Santhera Pharmaceuticals, Summit Therapeutics, Catabasis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
76
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day

Liestal, Switzerland, Oxford, UK, Cambridge, Mass., 6 December 2017: Santhera Pharmaceuticals (SIX: SANN), Summit Therapeutics (NASDAQ: SMMT; AIM: SUMM), Catabasis Pharmaceuticals (NASDAQ: CATB) and Duchenne UK are pleased to announce a collaboration to host a Duchenne Muscular Dystrophy (DMD) Awareness Day today in London.

The half-day event will feature presentations by key opinion leaders representing clinical practitioners, industry professionals and the patient group Duchenne UK. Professor Dame Kay Davies FRS of the University of Oxford, Dr Rosaline Quinlivan MD of the National Hospital for Neurology and Neurosurgery and Professor Thomas Voit MD of Great Ormond Street Hospital and University College London will deliver keynote addresses focusing on the biology and aetiology of the disease, and the current treatment landscape.

The sponsoring companies will also present on their respective development programmes for new therapeutic options for DMD and the future outlook for patients.

Emily Crossley, Co-Founder and joint Chief Executive Officer of Duchenne UK, and Chair of the event, commented: "We are excited to be taking part in this comprehensive DMD awareness day. Duchenne UK is committed to working globally with industry to fund and accelerate drug development, and is delighted to be publicly collaborating with innovative companies such as Summit, Santhera and Catabasis. We are united in our mission to end Duchenne, and this event will raise much-needed awareness about this disease and highlight the growing pipeline of potentially life-changing treatments."  

A live audio webcast of the event will be available at the following link: https://edge.media-server.com/m6/p/nacwa6fn . A replay will be available on the supporting companies' websites the day after the event.

For further information of the event, please contact: DMDevent@consilium-comms.com +44 (0)20 3709 5700

-  ENDS  -

About Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy is the most common fatal genetic disease diagnosed in childhood. Children born with DMD cannot produce the protein dystrophin which is vital for muscle strength and function. Muscle weakness starts in early childhood. Many use a wheelchair by around the age of 12. As deterioration continues it leads to paralysis and early death, often in their 20s. It almost exclusively affects boys. There is no treatment or cure. In the UK there are around 2,500 boys affected and around 300, 000 worldwide. It is classified as a rare disease.

About Catabasis At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART Linker SM  platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com .

About Duchenne UK Duchenne UK is a lean, ambitious and highly focused charity with a clear vision: to fund and accelerate treatments and a cure for Duchenne muscular dystrophy. The charity has been formed by the coming together of Joining Jack and Duchenne Children's Trust, the two biggest funders of research in the UK in the last three years. Its president is HRH The Duchess of Cornwall. Its patrons include the broadcasters Krishnan Guru-Murthy and Mary Nightingale, and the sports stars Owen Farrell, Kris Radlinski and Andy Farrell.

About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), Santhera has filed a Marketing Authorization Application in the European Union and Switzerland for DMD patients with respiratory function decline who are not taking glucocorticoids. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product - omigapil - for congenital muscular dystrophy (CMD), both also areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com .

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

Contact information:

Santhera Pharmaceuticals Sue Schneidhorst, Head Group Communications Europe: +41 61 906 89 26 US: +1 646 586 2113

Summit Therapeutics Richard Pye, Senior Director, Corporate Affairs & Communications +44 (0)1235 443 951

Catabasis® Pharmaceuticals, Inc. Andrea Matthews, Vice President, Corporate Affairs +1 617 349 1971 amatthews@catabasis.com

Consilium Strategic Communications Amber Fennell, Jessica Hodgson, Sukaina Virji +44 (0)20 3709 5700 DMDevent@consilium-comms.com  

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...c090ba20c8

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 146

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Satellite NTN's $3.22B Promise Needs Real Receipts

Updated Category News Views 17

Dead zones over oceans, deserts, and flight paths are finally becoming a serious commercial problem, not merely a neat engineering demo. That is the muscle behind the satellite non-terrestrial network, or NTN, pitch: connect aircraft, vessels, remote assets, and scattered sensors where terrestrial networks simply do not reach. MarketsandMarkets projects this market will...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 73

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 142

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 144

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 41

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 95

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 52

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading

Top 5 Most Recently Viewed Articles

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer

Updated Category News Views 219

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer NN, Inc. (NASDAQ: NNBR), a leader in high-precision industrial components, has recently appointed Tim Erro as its new Chief Commercial Officer. In this role, Mr. Erro will spearhead NN's global commercial efforts, enhancing the company's strategic initiatives aimed at business growth and development. Under the...

Continue Reading
Horizon Robotics Unveils Innovations in Smart Driving Solutions

Updated Category News Views 321

Horizon Robotics Unveils Innovations at IAA Mobility 2025 Horizon Robotics, a pioneer in smart driving solutions for passenger vehicles, recently demonstrated its cutting-edge technologies at IAA Mobility 2025. This platform not only highlights the company's dedication to smart mobility but also marks a significant step in its global outreach by establishing new...

Continue Reading
Nuvoton Technology Unveils Exciting New Industrial ICs

Updated Category News Views 157

Nuvoton Technology's Innovative BM-ICs for Industrial Applications Nuvoton Technology Corporation Japan (NTCJ) is set to introduce groundbreaking industrial battery monitoring integrated circuits (BM-ICs) designed for 48V batteries. These new products, named "KA49701A" and "KA49702A," are scheduled to enter mass production soon. Enhanced Safety Features in Battery System...

Continue Reading
Celebrate National Coffee Day with Atlas Coffee Club's Free Offer

Updated Category News Views 206

Celebrate National Coffee Day with Atlas Coffee Club Atlas Coffee Club is thrilled to celebrate National Coffee Day with a fantastic offer that every coffee lover is sure to appreciate. From now until October 2, you can snag a complimentary 12-ounce bag of single-origin coffee just by subscribing. All you need to do is cover the shipping fee, and you’re all set! The...

Continue Reading
Crypto Market Dynamics: Bitcoin and XRP Show Potential Gains

Updated Category News Views 264

Bitcoin Approaches Key Resistance Levels Recently, Bitcoin has seen a substantial surge as it has crossed a significant resistance level around $102,000, signifying a bullish sentiment in the market. This progression highlights a critical test as Bitcoin now looks to penetrate a key psychological and technical barrier at $105,000. The macroeconomic backdrop is favorable,...

Continue Reading